INTRODUCTION 61
Pneumocystis organisms are fungal parasites that colonize the lungs of mammals (Skalski et 62 al. 2015; Thomas and Limper 2004) . Each Pneumocystis species displays strict host 63 specificity for a single mammalian species. The species infecting humans is Pneumocystis 64 jirovecii. In immuno-compromised patients, P. jirovecii can turn into an opportunistic 65 pathogen causing Pneumocystis jirovecii pneumonia (PCP), a severe disease which can be 66 fatal. Standard antifungals targeting the fungal cell membrane integrity or synthesis are not 67 effective against P. jirovecii, possibly because of the presence of cholesterol instead of 68 ergosterol in its membrane (Kaneshiro et al. 1994 ; Russian and Kovacs 1998). The most 69 efficient drug currently used is cotrimoxazole, a combination of trimethoprim and 70 sulfamethoxazole. These two molecules are inhibitors of enzymes involved in the 71 biosynthesis of folic acid, a metabolite required for the biosynthesis of essential cellular 72 compounds. Cotrimoxazole is active against both cellular forms present during Pneumocystis 73 infection: the trophic form which is the predominant one and apparently devoid of wall, and 74 the ascus form which would be issued from a sexual cycle and has a thick wall (Aliouat et al. 75 2009; Itatani and Marshall 1988; Thomas and Limper 2007) . The use of cotrimoxazole for 76
prophylaxis and treatment of PCP since the late 1980s (Kovacs et al. 2001 ) correlated with the 77 detection of specific mutations within the active site of the dihydropteroate synthase, the 78 target of sulfamethoxazole (Lane et al. 1997; Ma et al. 1999; Nahimana et al. 2003) . Because 79 of the emerging resistance to cotrimoxazole and because this drug can cause side effects such 80 as intolerance and toxicity, it is of the utmost importance to find new treatments and to 81 identify new drug targets to fight P. jirovecii. 82 One promising class of antifungals is echinocandins. Caspofungin (CAS), 83 anidulafungin, and micafungin are cyclic hexapeptides with fatty acyl side chains which are 84 non-competitive inhibitors of the catalytic subunit of the 1,3-β glucan synthase enzymatic 85 complex (Schmatz et al. 1990 ). β-glucan molecules are homopolymers of β-1,3 linked D-86 glucose with β-1,6 linked D-glucose side chains in minority. β-glucans are important 87 components of the fungal cell wall, together with mannoproteins and chitins (Bowman and 88 Free 2006) . All these components are usually involved in the host immune recognition in 89 typical fungal pathogens (Amarsaikhan and Templeton 2015; Cambi et al. 2008 ). In contrast, 90
Pneumocystis organisms would be unable to synthesize chitin, and harbour only β-glucans 91 and mannoproteins, which, however, lack hyper-mannose glycosylation (Ma et al. 2016 ). The 92 1,3-β glucan synthase enzymatic complex is an ideal drug target to fight pathogenic fungi 93 because it (i) is essential for these microorganisms, (ii) has no human counterparts, and (iii) is 94 easily reachable by drugs because of their localization at the fungal surface, anchored in the 95 cellular membrane. Four studies reported initially the efficacy of echinocandins and related 96 compounds against Pneumocystis carinii, the species infecting rats (Powles et al. 1998; 97 Schmatz et al. 1990; Schmatz et al. 1995; Sun and Zhaohui 2014) . Consistent with their lack 98 of or poor glucan content, trophic forms appeared to be much less sensitive to CAS than asci 99 (Cushion et al. 2010 ). Combining caspofungin with cotrimoxazole provided an addictive 100 effect, improving the clearance of infection by Pneumocystis murina, the species infecting 101 mice (Lobo et al. 2013 ). However, the response to echinocandins of the human pathogen 102 P. jirovecii could be different than those of the models P. carinii and P. murina. Indeed, the 103 genomic coding sequences of the two latter species present a mean divergence of ca. 20% at 104 nucleotide level from those of P. jirovecii (Stringer 1996) . The available clinical reports 105 concerning the issue are contradictory so that the efficacy of caspofungin against P. jirovecii 106 remains unclear. Indeed, the combination of caspofungin with cotrimoxazole was reported to 107 have cleared several PCP episodes, two in HIV-positive patients (Ceballos et al. 2011; Lee et 108 al. 2016 ), seven in transplant recipients (Utili et al. 2007; Tu et al. 2013) , and one in a 109 pediatric case (Beltz et al. 2006) . Caspofungin alone was reported to have been successful in a 110 patient undergoing bone marrow transplantation (Annaloro et al. 2006) , in a Wegener's 111 granulomatosis patient (Hof and Schnülle 2008) , as well as in eight out of ten HIV-infected 112 patients (Armstrong-James et al. 2011 ). However, failure of treatment using caspofungin 113 alone was described in four HIV-negative (Kim et al. 2013 ) and two cancer patients (Kamboj 114 et al. 2006). 115 In S. cerevisiae, the GSC1, GSC2, and GSC3 genes (also called FKS1 to 3) encode 116 different catalytic subunits of the 1,3-β glucan synthase enzymatic complex. The GSC1 gene 117 is active during the vegetative growth whereas GSC2 and GSC3 are expressed during 118 sporulation (Bowman and Free 2006; Mazur et al. 1995) . The presence of a unique gsc1 gene 119 encoding the 1,3-β glucan synthase catalytic subunit in the genome of P. carinii and the 120 inhibition of the Gsc1 protein by the pneumocandin L-733,560, a compound structurally very 121
close to echinocandins, were demonstrated (Kottom and Limper, 2000) . These observations 122 also suggest that echinocandins might become useful for prevention and treatment of PCP in 123 the future. 124 1,6-β glucans are less abundant than 1,3-β glucans in fungal cell walls, and act as a 125 flexible glue between the other components of the wall (Kollár et al. 1997) . At least ten genes 126 are involved in the biosynthesis of 1,6-glucan in S. cerevisiae (Shahinian and Bussey, 2000) . 127 These genes have also no homologs in human genome. Inhibitors of the 1,6-β glucan 128 synthesis were recently discovered (Kitamura et al. 2009 ; Kitamura 2010). These inhibitors 129 target the membrane protein kre6 and show an important in vitro activity against Candida 130 species and S. cerevisiae (Kitamura 2010). S. cerevisiae harbours the Kre6 enzyme as well as 131 a homolog called SknI sharing 66% sequence identity with Kre6. Unlike the KRE6 gene, the 132 deletion of the SKN1 gene does not show any effect on growth or 1,6-β glucan levels within 133 the wall, suggesting that the Skn1 enzyme is less important than the Kre6 enzyme, at least in 134 the laboratory conditions (Roemer et al. 1993) . The presence of a unique kre6 gene and the 135 sensitivity of the Kre6 enzyme to the 1,6-β glucan inhibitors were recently demonstrated in 136 P. carinii (Kottom et al. 2015) . These observations suggest that 1,6-β glucan inhibitors might 137 become useful new drugs against P. jirovecii. 138 The identification and characterization of the P. jirovecii gsc1 and kre6 genes has not 139 been carried out yet. Despite that the in vitro culture method for this pathogen published by 140 Schlidgen et al. (2014) is not widely established yet, this task is now possible because of the 141 recent release of the genome sequence of P. jirovecii by two groups (Cissé et al. 2012; Ma et 142 al. 2016 ). In the present study, we report the identification of these two genes within the 143 P. jirovecii genome sequence, as well as the assessment of their function by the 144 complementation of the respective deleted orthologous gene of S. cerevisiae. 145 In order to perform complementation controls, the S. cerevisiae GSC1 and KRE6 genes were 202 amplified by PCR from DNA from the wild type strain BY4741 extracted as described 203 previously (Lo Presti et al. 2007 ). The genes are respectively 5,631 and 2,163 pbs. PCR 204 primers and conditions are given in Tables S1 and S2, respectively. Primers were synthesized  205 by Microsynth (Balgach, Switzerland). For oriented cloning, the primerswere designed to 206 create unique restriction sites at ends of the PCR products. The latter were extracted using the 207 QIAquick gel extraction kit (Qiagen, Basel, Switzerland), digested by BamHI and PstI 208 restriction enzymes and cloned into the p415GPD expression vector (GSC1), or digested by 209
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BamHI and SalI and cloned into p416GPD (KRE6). 210 211
Transformation of S. cerevisiae deletants 212
The recombinant plasmids p416GPD.Pjgsc1, p416GPD.Pjkre6, p415GPD.ScGSC1, and 213 p416GPD.ScKRE6 were introduced into their corresponding S. cerevisiae deletant by 214 transformation for uracil (p416GPD) or leucine (p415GPD) prototrophy using the one-step 215 method (Chen et al. 1992) . In order to be used as controls in the complementation tests 216 involving selection of plasmids, the deletants and the wild type strain BY4741 were 217 transformed with the empty p416GPD or p415GPD. in the 1,6-β glucan biosynthesis, and also characterized its function by complementation. Both 333 these heterologous complementations were partial, whereas those with the homologous S. 334 cerevisiae gene were complete. This could be explained by the fact that we used a vector with 335 a strong promoter for the complementation, and that the high expression of the gene was toxic 336 (Romanos et al. 1992 ). However, we repeated the experiments using a weaker promoter and 337 the results were similar (data not shown). Such partial complementation is not surprising since 338 it often occurred in our previous complementation studies. Indeed, the S. cerevisiae dhfs and 339 brl1 deletants complemented with the P. jirovecii and P. carinii genes presented a reduced 340 growth rate (Lo Presti et al. 2007; Luraschi et al. 2015) . Partial complementation may result 341 from a poor fitness of the enzyme in the heterologous cellular environment. For example, the 342 reduced growth rate of the complemented kre6 deletant could be due to a persistent stress in 343 the cell wall, leading to a perturbation of the cell wall integrity. Impaired synthesis due to a 344 different codon usage could also play a role. We reported partial complementation also in 345 homologous complementation of brl1 (Lo Presti et al. 2009 ). This suggests the possible 346 importance of a different gene dosage due to the plasmidic rather than chromosomic location, 347 or of the use of a non natural promoter which provides a constitutive rather than temporally 348 regulated expression, and/or an inadequate level of expression. 349
The Gsc1 subunit catalyzes the polymerization of uridine diphosphate-glucose into the 350 1,3-β glucan core, an insoluble molecule required for the cell wall assembly (Shematek et al 351 1980). The GSC1 and GSC2 genes are a redundant essential pair, i.e., the double deletion 352 mutant is not viable, while the single mutants is viable (Inoue et al. 1995; Mazur et al. 1995). 353 Thus, the growth of the gsc1 deletant in absence of CAS in our experiments was probably 354 supported by the expression of GSC2. In P. carinii, only one gsc1 gene was found using 355
Southern blot analyses (Kottom and Limper 2000) . The gsc1 gene is also unique in P. 356 jirovecii according to our BLAST searches in the two proteomes presently available. 357 Consequently, this gene is likely to be essential in P. jirovecii and the protein it encodes a 358 good potential drug target. This is true even if this gene is active mostly in the asci because it 359 is thought that production of asci constitutes an obligate stage of the life cycle (Cushion and  360 Stringer 2010; Hauser 2014), and that these forms might be the particles responsible for the 361 transmission of the fungus between hosts via the airborne route (Cushion et al. 2010; Martinez 362 et al. 2013) . 363
The Kre6 enzyme is anchored to plasma, Golgi, and reticulum endoplasmic 364 membranes. It is involved in the synthesis of 1,6-β glucan which is also an essential 365 component of the fungal cell wall. The function of this enzyme remains unclear. It is thought 366 to be a transglucosidase contributing to the construction of a protein-bound glucan-structure 367 which acts as an acceptor site for the 1,6-β-glucan addition at cell surface (Montijn et al. 368 1999). In S. cerevisiae, this Golgi membrane glycoprotein has a homolog, Skn1, which is 369 structurally related and has a similar function but which plays a less important role. The gsc1 and kre6 genes and their encoded proteins predicted in the two available P. 380 jirovecii genomes were not identical. In both cases, the few synonymous SNPs observed can 381 be attributed to natural polymorphisms between these isolates originating from Switzerland 382 and USA. As far as the Gsc1 proteins are concerned, the 27 amino acids segment missing 383 within one of them may also be a natural polymorphism because (i) the shortened enzyme is 384 functional as demonstrated in the present work, (ii) the segment is not part of the conserved 385 glucan synthase domains, and (iii) the absence is associated to five bp inserted in a region 386 spanning only 24 bp, a configuration which is unlikely for sequencing errors. As far as the 387
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